Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: SKX stock price vs IOVA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at IOVA's multiple
Needs IOVA P/E.
Implied fair value · at SKX's multiple
Needs EPS (TTM) is negative, SKX P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SKX FY 2024 (ended Dec 31, 2024) · IOVA FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 100% equity / 0% debt · EV / Revenue 13.99x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
SKECHERS USA INC · implied price per share
Bear
$27.69
Base
$31.68
Bull
$36.87
IOVANCE BIOTHERAPEUTICS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.18x
0.00x
Net debt / EBITDA
Leverage against operating earnings
-0.46x
0.83x
Cash and equivalents
Liquid reserves on the balance sheet
$1.23B
$296.98M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
$774.71M
$1.00M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
